Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Population-based Study
100%
Pediatric Glioma
100%
Population-based Cancer Registry
60%
Young Adolescents
50%
Netherlands
50%
Preadolescent children
50%
Young children
50%
Relapsed or Refractory Acute Myeloid Leukemia
50%
Infant Patients
50%
Gemtuzumab Ozogamicin
50%
Vidaza
50%
Azacitidine
50%
Pediatric Patients
50%
Population-based Cohort Study
50%
Sex-related
50%
Group Studies
50%
Juvenile Myelomonocytic Leukemia
50%
Phase II Study
50%
Glioma Subtypes
50%
Survival Disparities
50%
Myelodysplastic Syndrome
50%
Children with Cancer
50%
Belgium
50%
Data Quality
50%
Tumor
50%
Registry Research
50%
Data Reporting
50%
Survival Outcomes
41%
Registration Practices
36%
Age Groups
35%
Standardized Incidence Ratio
30%
Neuroblastoma
30%
Neutralizing Effect
25%
Incidence Characteristics
25%
Diffuse Glioma
25%
Tumor Characteristics
25%
Survival Characteristics
25%
Sex Differences
25%
Aging Characteristics
25%
Survival Gap
25%
High Risk
25%
Treatment Characteristics
25%
Central Nervous System Tumors
20%
Acute Lymphoblastic Leukemia
20%
Minimal Residual Disease
20%
Belgian
20%
Cancer Incidence
20%
Confidence Interval
20%
Cancer Mortality
20%
Population-based
16%
Medicine and Dentistry
Pediatrics
100%
Ganglioglioma
100%
Central Nervous System Tumor
83%
Cancer Registry
66%
Tumor
55%
Azacitidine
50%
Toddlers
50%
Inotuzumab Ozogamicin
50%
Myelodysplastic Syndrome
50%
Juvenile Myelomonocytic Leukemia
50%
Acute Lymphoblastic Leukemia
50%
Pediatrics Patient
50%
Ganglioneuroblastoma
50%
Pediatric Cancer
50%
Long Term Survival
50%
Cancer Incidence
33%
Cancer Mortality
33%
Sex Differences
25%
Malignant Neoplasm
22%
Hematopoietic Stem Cell Transplantation
20%
Minimal Residual Disease
20%
Acute Myeloid Leukemia
16%
Rhabdomyosarcoma
16%
Cancer
16%
Cancer Epidemiology
16%
Cancer Types
16%
Cancer Survival
16%
Overall Survival
15%
Survival Rate
11%
Medulloblastoma
11%
Ependymoma
11%
Disease
10%
Vein Occlusion
10%
Transplantation
10%
Allograft
10%
Pharmacokinetics
10%
Childhood Cancer
5%
Survival Analysis
5%
Recommended Drug Dose
5%
Adverse Event
5%
Bone Marrow Toxicity
5%
Diseases
5%
Hematologic Malignancy
5%
Clinical Trial
5%
